LCA reports for Johnson & Johnson Innovative Medicine sponsored phase-2, 3, 4 clinical trials

Objective: To calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in phase-1, 2, 3, and 4 clinical studies spanning multiple disease areas

Design: Retrospective analysis

Data source:  Data collected by Johnson & Johnson Innovative Medicine during study conduct

Studies included:  Johnson & Johnson Innovative Medicine sponsored 77242113PSO2001 (ClinicalTrials.gov: NCT05364554), 42756493BLC2002 (ClinicalTrials.gov: NCT03473743), 54767414MMY3012 (ClinicalTrials.gov: NCT03277105), VAC18193RSV3006 (ClinicalTrials.gov: NCT05070546), R092670PSY3016 (ClinicalTrials.gov: NCT04072575), and 28431754DIA4032 (ClinicalTrials.gov: NCT04288778) clinical studies conducted between 2018-2023

Main outcome: measure CO2 equivalents (CO2e) for in-scope clinical trial activities calculated according to Intergovernmental Panel on Climate Change (IPCC) 2021 impact assessment methodology.

Methods
Retrospective analysis of recently completed clinical studies leveraging internal data held by Johnson & Johnson Innovative Medicine. The LCAs were conducted under a dynamic and iterative approach in accordance with ISO 14040/44 standards, and peer reviewed by a third party.